Octapharma

Octapharma AG, founded in 1983, is a family-owned pharmaceutical company, and bills itself as "one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines[3]."

Octapharma AG
Private
IndustryPharmaceutical industry
Founded1983
FounderWolfgang Marguerre 
Headquarters
Lachen
,
Switzerland
Number of locations
31
Productsoctanate; octanine-F; wilate; Nuwiq; octagam; gammanorm; rhesonativ; panzyga; albunorm; octaplas; atenativ; octaplex; octaplasLG; fibryga
See complete products listing.
RevenueEuro 2.2 billion (2019)[1]
Number of employees
9,307 (2019)[2]
Websitewww.octapharma.com

Products

Patients in 113 countries are treated with products in the following therapeutic areas:

  • Haematology: high-purity coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease.
  • Immunotherapy: immunomodulation or immunoglobulin replacement therapy for the treatment of immune-mediated diseases and deficiencies (immune disorders including autoimmune diseases and antibody deficiency) by inducing, enhancing, or suppressing an immune response.
  • Critical Care: human plasma and protein products for treating critically ill or injured patients in intensive care and emergency medicine settings.[3]

History

Octapharma was founded in 1983. In the name Octapharma, the “octa” is derived from the Greek word for eight, named after the factor which is deficient in haemophilia A patients. Octapharma’s inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.

The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines.

Products

Octapharma medicines treat a broad range of rare and life-threatening congenital and acquired diseases:

- bleeding disorders (hemophilia A / B and VWD) - over 300 types of primary and secondary immune deficiencies - numerous auto-immune and neurological disorders - acute conditions/in critical care (including trauma and burn victims) - cancer patients and during major surgeries - new-borns are also protected in case of Rh negative pregnancies

Production

Octapharma converts source plasma into plasma protein products through fractionation and processing. Each therapy created is controlled, fractionated, purified, virus inactivated and inspected before being used.

Octapharma owns six production facilities in Austria, France, Germany, Sweden and Mexico, and also 13 plasma donation centres in Europe and 86 the United States. Octapharma collects plasma and manufactures it into lifesaving plasma-derived therapies.

Notes and references
  1. Annual report 2018 https://www.octapharma.com/news/press-release/2020/octapharma-group-delivered-strong-growth-in-both-sales-and-operating-income-in-2019/
  2. Annual report 2018 https://www.octapharma.com/news/press-release/2020/octapharma-group-delivered-strong-growth-in-both-sales-and-operating-income-in-2019/
  3. Octapharma Website http://www.octapharma.com/en/patients/diseases-therapies.html

See also
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.